Current Report Filing (8-k)
August 05 2020 - 11:03AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): August 3, 2020
GLOBAL
WHOLEHEALTH PARTNERS CORPORATION
(Exact
name of registrant as specified in its charter)
Nevada
|
000-56035
|
46-2316220
|
(State
or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification No.)
|
2227
Avenida Oliva
San
Clemente, CA
|
92673
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code (714) 392-9752
N/A
(Former name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Section
8 - Other Events
Item
8.01 Other Events.
On
August 3, 2020, Global Wholehealth Partners Corporation (the “Company”) received a Letter of Authorization from
Healgen Scientific Limited which authorizes the Company to sell Healgen Scientific Limited’s SARS-COV-2 IgG/IgM
Antibody Whole Blood, Serum and Plasma. As of May 29, 2020, Healgen Scientific Limited has received Emergency Use
Authorization for the Healgen COVID-19 IgG/IgM rapid test cassette (WB/S/P) from the Food and Drug Administration.
The
Letter of Authorization from Healgen Scientific Limited is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K
and incorporated herein by this reference.
Section
9 – Financial Statement and Exhibits
Item 9.01 Financial Statements and Exhibits.
Exhibit
No.
|
|
Document
|
|
Location
|
99.1
|
|
Healgen Scientific Limited
Letter of Authorization
|
|
Filed Herewith.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
GLOBAL
WHOLEHEALTH PARTNERS CORPORATION
(Registrant)
|
Date:
August 5, 2020
|
By:
/s/ Charles Strongo
Charles Strongo
Chief Executive Officer
|
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Wholehealth Partn... (CE) (USOTC:GWHP)
Historical Stock Chart
From Sep 2023 to Sep 2024